Trump Picks New FDA Commissioner Amid Controversy

The nomination of Heidi Overton, MD, PhD, as the new FDA commissioner has sent shockwaves through the healthcare community. As a top White House aide, Overton has been a key figure in President Trump's health initiatives, but her qualifications and stance on various issues have raised concerns.

Overton has a background in medicine and has worked on several of Trump's health initiatives, including efforts to lower drug prices and promote innovation. However, her views on abortion and vaccination have been criticized by some.

If confirmed, Overton would face a number of challenges, including balancing competing priorities and navigating the complex world of FDA regulations. Her predecessor, Marty Makary, MD, MPH, resigned in May, leaving behind unfinished projects and a legacy of controversy.

Makary's tenure was marked by complaints from health industry executives and anti-abortion activists, who criticized his handling of flavored e-cigarettes and other issues. The agency also faced criticism for its handling of biotech drugs and its decision to allow more unauthorized electronic cigarettes and nicotine pouches onto the market.

The nomination of Overton has been met with skepticism by some lawmakers, who have expressed concerns about her qualifications and stance on various issues. Democratic senators have slammed the nomination, with Sen. Patty Murray (D-Wash.) calling Overton a "far-right, anti-abortion extremist who has no business leading the FDA."

## Challenges Ahead for the FDA

The FDA faces a number of challenges, including navigating the complex world of regulations and balancing competing priorities. The agency must also contend with the ongoing COVID-19 pandemic and the need to develop and approve new treatments and vaccines.

In addition to the challenges posed by the pandemic, the FDA must also address the growing concern about the safety of antidepressants and other widely used therapies. The agency is currently reviewing the safety of these medications, including whether they may increase the risk of autism and other disorders when used during pregnancy.

## FDA's Priorities Under Trump

Under President Trump, the FDA has taken a number of steps to address the concerns of conservative lawmakers and the health movement. The agency has set up extra hurdles for vaccine testing and blocked the publication of research into the effectiveness of COVID-19 shots.

The FDA has also been working with the White House to finalize a first-of-its-kind definition of ultraprocessed foods, which Kennedy blames for elevated rates of diabetes, obesity, and other chronic conditions. The agency has also proposed a rule change that would require food manufacturers to notify regulators before introducing new ingredients or additives into processed or packaged foods.

| FDA Commissioner | Tenure | Background | | --- | --- | --- | | Heidi Overton, MD, PhD | Pending | Top White House aide, worked on Trump's health initiatives | | Marty Makary, MD, MPH | May | Resigned, left behind unfinished projects and controversy |

| FDA Priorities | Description | | --- | --- | | Peptide regulation | Ease access to peptides popular with wellness influencers and celebrities | | Ultraprocessed foods | Finalize definition of ultraprocessed foods and require notification of new ingredients or additives | | Antidepressants | Review safety of antidepressants, including risk of autism and other disorders when used during pregnancy |